ebselen has been researched along with Cancer of Ovary in 1 studies
ebselen : A benzoselenazole that is 1,2-benzoselenazol-3-one carrying an additional phenyl substituent at position 2. Acts as a mimic of glutathione peroxidase.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The chemoprotective effects of combined ebselen and allopurinol in breast (MTLn3) and ovarian (NuTu-19) cancer models using a repeated cisplatin dosing schedule (6 mg/kg i." | 1.33 | Combined oral delivery of ebselen and allopurinol reduces multiple cisplatin toxicities in rat breast and ovarian cancer models while enhancing anti-tumor activity. ( Gu, R; Kil, J; Lynch, ED; Pierce, C, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lynch, ED | 1 |
| Gu, R | 1 |
| Pierce, C | 1 |
| Kil, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety and Efficacy Study of SPI-1005 for Prevention of Chemotherapy Induced Hearing Loss[NCT01451853] | Phase 2 | 80 participants (Anticipated) | Interventional | 2018-01-15 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for ebselen and Cancer of Ovary
| Article | Year |
|---|---|
Combined oral delivery of ebselen and allopurinol reduces multiple cisplatin toxicities in rat breast and ovarian cancer models while enhancing anti-tumor activity.
Topics: Administration, Oral; Allopurinol; Animals; Antineoplastic Agents; Azoles; Cell Line, Tumor; Chemopr | 2005 |